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to filter for potential phenotype-relevant target genes. After cloning 
3’-UTR sequences containing predicted miRNA binding sites into 
psiCHECK2 or pmiRGLO vectors reporter gene assays were per-
formed to confirm RNA interference of selected candidate miRNAs 
with their respective target genes.
Results: Of 754 miRNAs, 201 were detected in both tissue types. 
Two miRNAs were differentially expressed in the hippocampus 
relative to the cortex (miR-34c-5p: 7.2-fold higher [q = 0.01], miR-
212-3p: 3.8-fold lower [q = 0.01]). Bioinformatic analysis and fil-
tering for target genes identified 9 genes important for drug efflux, 
neuronal regulation, and signal transmission. Reporter gene experi-
ments confirmed 3 target genes posttranscriptionally regulated by 
miR-34c-5p (GABBR2, GABRA3, GRM7) and 3 target genes regu-
lated by miR-212 (ABCG2, SOX11, ADCY1).
Conclusion: Differential regulation of 2 miRNAs could contribute 
to an altered function of several genes resulting not only in an imbal-
anced neuronal excitability but also in impaired neural differentia-
tion and accelerated drug export. These data suggest multifactorial 
alterations involving miRNA-mediated regulation leading to phar-
macoresistance in epilepsy.
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Introduction: Tolperisone, which is indicated in the treatment of acute 
muscle spasms in back pain and spasticity in neurologic diseases, is a 
centrally acting muscle relaxant. Although the metabolism of tolperisone 
is primarily mediated by CYP2D6, CYP2C19, CYP1A2, and CYP2B6 
are also involved in the biotransformation of tolperisone. Among 3 
drug-metabolizing enzymes, CYP2C19 is a highly polymorphic enzyme. 
The aim of this study was to investigate the effects of CYP2C19 genetic 
polymorphism on the pharmacokinetics of tolperisone.
Patients (or Materials) and Methods: Twenty-six healthy Korean 
subjects were selected and divided into 3 different groups according 
to CYP2C19 genotype, CYP2C19EM (CYP2C19*1/*1, n = 12), 
CYP2C19IM (CYP2C19*1/*2 or *1/*3, n = 7), and CYP2C19PM 
(CYP2C19*2/*2, *2/*3 or *3/*3, n = 7). After overnight fasting, 
each subject received a single 150-mg oral dose of tolperisone. Blood 
samples were collected up to 12 hours after drug intake, and plasma 
concentrations of tolperisone were measured by using LC-MS/MS 
analytical system.
Results: Cmax in CYP2C19PM group was significantly higher 
than that in CYP2C19IM and CYP2C19EM (P = 0.0017 for 
all). AUCinf in CYP2C19PM was also significantly higher than 
that in CYP2C19IM and CYP2C19PM group (P < 0.001 for all). 
Corresponding values for tolperisone in CYP2C19EM and IM groups 
were almost similar (P > 0.05). Apparent oral clearance (CL/F) of 
tolperisone in CYP2C19PM group was 84% lower than that in 
CYP2C19IM group (618 [379] vs 2900 [1343] L/h; P = 0.0010). 
Differences in other parameters of tolperisone between 3 genotype 
groups were not statistically significant.
Conclusion: In Korean healthy subjects, pharmacokinetics of tolp-
erisone are not only influenced by CYP2D6 genotypes but also influ-
enced by CYP2C19 genotypes. Particularly, CYP2C19PM subjects 
had markedly increased plasma concentration of tolperisone com-
pared with CYP2C19EM or CYP2C19IM subjects.
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Introduction: Carbamazepine (CBZ) causes hypersensitivity reac-
tions in a small proportion of patients. There is strong evidence that 
specific human leukocyte antigen (HLA) alleles are associated with 
a higher risk of developing CBZ-induced hypersensitivity. HLA-
A*3101 represents the latest example and is associated with several 
clinical phenotypes of CBZ-induced hypersensitivity in Caucasian 
and Japanese patients. In this study, we aimed to determine whether 
HLA-A*31:01 is functionally implicated in the development of a 
drug-specific immune response in our patient.
Patients (or Materials) and Methods: Peripheral blood mononuclear 
cells (PBMCs) were isolated from a patient with CBZ hypersensitivity 
and the presence of drug-responsive T cells confirmed in vitro using 
the lymphocyte transformation test (LTT). The study was approved 
by the local ethics committee and informed consent was obtained 
from the patient. Drug-specific T cells were enriched in a 4-week 
induction culture and their reactivity tested with enzyme-linked 
immunospot (ELISpot) technique and 51Cr-release assay. T-cell 
clones (TCCs) were generated by serial dilution; characterization 
included CD phenotype, HLA restriction and cytokine profile.
Results: PBMCs responded to CBZ in the LTT with a stimulation 
index (SI) of 15.9. After the 4-week enrichment culture, T-cells were 
shown to secret Interferon-γ (IFN-γ ) and kill 51Cr-loaded target cells 
when exposed to CBZ. Thirty-two CBZ-specific TCCs were gener-
ated; they secreted IFN-γ , interleukin-13 and cytolytic molecules such 
as granzyme B, perforin, and FasLigand. The majority of TCCs were 
CD4+ and T-cell activation was restricted by HLA class II alleles, 
i.e. HLA-DR and -DP. These TCCs proliferated in the presence of 
both CBZ and antigen presenting cells (APCs) expressing HLA-
A*31:01 and HLA-DRB1*04:04, but also in the presence of HLA-
DRB1*04:04+ APCs lacking HLA-A*31:01. HLA-DRB1*04:04 is 
known to be part of a common haplotype with HLA-A*31:01 in 
Caucasians.
Conclusion: We were able to stimulate a secondary immune response 
to CBZ in vitro using lymphocytes from a HLA-A*31:01+ hypersen-
sitive patient. CBZ-specific T cells of CD4+ phenotype were restricted 
by HLA class II alleles, and proliferated in the presence of CBZ and 
HLA-DRB1*04:04+ A*31:01- APCs revealing that a common hap-
lotype may contribute to the multi-clonal response seen in patients 
with CBZ hypersensitivity. Further studies are needed to confirm 
the association.
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Introduction: Two algorithms for acenocoumarol stable dose pre-
diction have been recently published. The first, developed by the 
EU-PACT group includes demographic (age, sex, weight, height, 
amiodarone cotreatment) and genetic variables (genetic variants 
in CYP2C9 and VKORC1 genes). The second one has been devel-
oped by our group (HULP algorithm) in a cohort of 147 patients 
with thromboembolic disease (VTD), including clinic-demographic 
